Publications by authors named "J L Kambou"
Background: A new serogroup A meningococcal conjugate vaccine (PsA-TT, MenAfriVac™) has been developed to combat devastating serogroup A Neisseria meningitis (MenA) epidemics in Africa. A mass immunization campaign targeting 1-29 year olds was conducted in Burkina Faso in December 2010. Protection of subsequent infant cohorts will be necessary through either introduction of PsA-TT into the routine Expanded Programme on Immunization (EPI) or periodic repeat mass vaccination campaigns.
View Article and Find Full Text PDFArticle Synopsis
- - In 2010, Burkina Faso debuted the meningococcal serogroup A vaccine (PsA-TT), leading to increased reports of Neisseria meningitidis serogroup W cases in 2012, prompting research into the reasons behind this rise.
- - Analysis of national surveillance data showed 5,807 meningitis cases in 2012, with 41% confirmed through lab tests; N. meningitidis serogroup W was the most common pathogen, accounting for 62% of isolates.
- - The study suggests that while more data is necessary, serogroup W is likely to continue causing sporadic cases and may lead to epidemics, highlighting the importance of ongoing, high-quality
Objective: The optimal long-term vaccination strategies to provide population-level protection against serogroup A Neisseria meningitidis (MenA) are unknown. We developed an age-structured mathematical model of MenA transmission, colonization, and disease in the African meningitis belt, and used this model to explore the impact of various vaccination strategies.
Methods: The model stratifies the simulated population into groups based on age, infection status, and MenA antibody levels.
Background: An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA-TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national prevention campaign, vaccinating 11·4 million people aged 1-29 years. We analysed national surveillance data around PsA-TT introduction to investigate the early effect of the vaccine on meningitis incidence and epidemics.
View Article and Find Full Text PDF